We found that MTR OralGem administration enhanced PD-1 expression in lung tumor-infiltrating CD4+ and CD8+ T effectors and boosted PD-L1 levels in DC and tumor cells, sensitizing the TME to anti-PD-1 immunotherapy in the syngeneic lung cancer model. The gene discussed is CD274; the disease is lung carcinoma.